Theriva Biologics Secures Regulatory Clearance for VIRAGE2 Phase IIa Trial

On July 7 2026, Theriva Biologics Inc. (NYSE American: TOVX) announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has granted approval to initiate the VIRAGE2 Phase IIa clinical trial. The study will evaluate a more frequent dosing regimen of the company’s oncolytic adenovirus, VCN‑01 (zabilugene almadenorepvec), in combination with standard gemcitabine/nab‑paclitaxel therapy in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC).

Trial Design and Objectives

  • Study Type: Single‑arm, single‑center, open‑label, proof‑of‑concept.
  • Population: First‑line PDAC patients with metastatic disease.
  • Intervention: Increased frequency dosing of VCN‑01 plus gemcitabine/nab‑paclitaxel.
  • Primary Endpoint: Safety and tolerability of the intensified dosing schedule.
  • Secondary Endpoints: Preliminary anti‑tumor activity, progression‑free survival, and overall survival metrics.

The VIRAGE2 protocol builds directly on the encouraging outcomes observed in the earlier VIRAGE study, which established the safety and anti‑tumor potential of VCN‑01 when administered once every 28 days. Regulatory authorities—namely the EMA and FDA—have acknowledged the promise of repeated VCN‑01 dosing, suggesting that a more aggressive schedule may yield superior clinical benefits.

Strategic Implications for Theriva

  1. Progression Toward a Pivotal Phase III Trial The design of VIRAGE2 is explicitly intended to refine the dosing regimen that will later underpin a pivotal Phase III trial. By demonstrating safety and early efficacy with a higher dosing frequency, Theriva can substantiate the rationale for a larger, randomized study.

  2. Accelerated Pathway to Market Successful completion of VIRAGE2 could expedite the company’s regulatory submissions in multiple jurisdictions, potentially shortening the time to first‑in‑class approval for a novel oncolytic platform in a high‑unmet‑need indication.

  3. Strengthening Investor Confidence The AEMPS authorization reflects regulatory confidence in Theriva’s science and operational capability. Coupled with the company’s market capitalization of $11.5 million and a recent share price of $0.2533, this milestone signals momentum that may attract additional capital.

Competitive Landscape

The oncolytic virus arena is rapidly evolving, with several biotech entities pursuing adenoviral vectors for solid tumors. Theriva’s focus on intratumoral delivery via intravenous and intravitreal routes, coupled with its unique “tumor‑cell‑death” trigger and immune‑stimulation profile, positions it distinctively within this cohort. The upcoming VIRAGE2 data will be pivotal in differentiating Theriva’s platform from competitors that rely on single‑dose regimens or less aggressive schedules.

Forward‑Looking Perspective

Theriva’s leadership is poised to interpret VIRAGE2 outcomes as a decisive step toward a definitive Phase III program. Should the safety profile remain robust and preliminary efficacy signals emerge, the company is likely to seek regulatory dialogue with the FDA and EMA to outline a global development strategy. Given the high unmet need in metastatic PDAC and the limited survival advantage of current standard therapies, a successful VIRAGE2 could catalyze a paradigm shift in how oncolytic viruses are integrated into first‑line treatment algorithms.

Theriva’s continued emphasis on refining dosing schedules, coupled with its proprietary adenovirus platform, underlines a commitment to delivering measurable clinical benefits. The AEMPS clearance serves as an endorsement of the company’s scientific merit and operational readiness—factors that will resonate with stakeholders across the oncology and investment communities as Theriva advances toward its next developmental milestones.